Legal Opinion
Pfizer, Inc. v. Ranbaxy Laboratories, Limited
Court of Appeals for the Federal Circuit
Decided August 2, 2006No. 2006-1179PublishedCited by 50 opinions
1Opinion of the Court
MICHEL, Chief Judge.
In this patent case concerning the prescription drug Lipitor®, which is used to reduce low-density lipoprotein (LDL) cholesterol levels, defendants-appellants Ranbaxy Laboratories Limited and Ranbaxy Pharmaceuticals, Inc. (collectively “Ranbaxy”) appeal from a final judgment of the United States District Court for the District of Delaware. Plaintiffs-appellees Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Co., Warner-Lambert Co. LLC, and Warner-Lambert Export, Ltd. (collectively “Pfizer”) filed four complaints, later consolidated into a single action,…
2Cases cited14 opinions
- United States v. United States Gypsum Co.Supreme Court of the United States · 1948
- Edward H. Phillips v. Awh Corporation, Hopeman Brothers, Inc., and Lofton Corporation, Defendants-CrossCourt of Appeals for the Federal Circuit · 2006
- Vitronics Corporation v. Conceptronic, Inc.Court of Appeals for the Federal Circuit · 1996
- Cybor Corporation v. Fas Technologies, Inc., and Fastar Ltd., Defendants-CrossCourt of Appeals for the Federal Circuit · 1998
- Allen Engineering Corporation v. Bartell Industries, Inc. And Darragh CompanyCourt of Appeals for the Federal Circuit · 2002
9 more not listed; retrieve them via the Exa API.
3Cited by50 opinions
- Hill-Rom Services, Inc. v. Stryker CorporationCourt of Appeals for the Federal Circuit · 2014
- Apple Inc. v. Motorola, Inc.Court of Appeals for the Federal Circuit · 2014
- Abbott Laboratories v. Sandoz, Inc.Court of Appeals for the Federal Circuit · 2009
- In Re Lipitor Antitrust LitigationCourt of Appeals for the Third Circuit · 2017
- In Re Lipitor Antitrust LitigationCourt of Appeals for the Third Circuit · 2017
45 more not listed; retrieve them via the Exa API.